Results 31 to 40 of about 938,592 (268)

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening

open access: yesHepatology Communications, EarlyView., 2022
Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff   +17 more
wiley   +1 more source

High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany : a prospective screening analysis of 28,809 patients [PDF]

open access: yes, 2012
Background and Aims: The prevalence of hepatitis C virus (HCV) antibodies in Germany has been estimated to be in the range of 0.4–0.63%. Screening for HCV is recommended in patients with elevated ALT levels or significant risk factors for HCV ...
Hintereder, Gudrun   +47 more
core   +2 more sources

Lipid metabolism and HCV infection [PDF]

open access: yes, 2010
Chronic infection by hepatitis C virus (HCV) can lead to severe liver disease and is a global healthcare problem. The liver is highly metabolically active and one of its key functions is to control the balance of lipid throughout the body.
Boulant, Steeve   +11 more
core   +1 more source

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms [PDF]

open access: yes, 2011
Background: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C.
Askarieh Galia   +109 more
core   +1 more source

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants [PDF]

open access: yes, 2010
Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease ...
Stefan Zeuzem   +36 more
core   +2 more sources

A long-range RNA–RNA interaction between the 5′ and 3′ ends of the HCV genome [PDF]

open access: yes, 2009
The RNA genome of the hepatitis C virus (HCV) contains multiple conserved structural cis domains that direct protein synthesis, replication, and infectivity. The untranslatable regions (UTRs) play essential roles in the HCV cycle. Uncapped viral RNAs are
C. Romero-Lopez   +3 more
core   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy [PDF]

open access: yes, 2010
Background: Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels.
Battegay, Manuel   +87 more
core   +2 more sources

Most common HCV genotypes in patients from north-eastern Croatia [PDF]

open access: yesActa Medica Academica, 2014
Objective. The aims of this study were to determine the HCV-RNA viral load, genotype distribution, risk factors and symptoms of HCVRNA positive viral load in HCV antibody-positive patients from north-eastern Croatia. Materials and methods. From January
Magdalena Perić   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy